We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus Yervoy (ipilimumab).
The regulatory body approved Opdivo plus Yervoy as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
Please note that Opdivo , as a single agent or in combination with Yervoy, was previously granted accelerated approval in MSI-H/dMMR CRC in adult and pediatric patients (12 years and older) who have progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
The latest FDA approval converts this second-line indication to full approval for Opdivo monotherapy and expands the indication for Opdivo plus Yervoy into the first-line setting.
Shares of BMY have risen 7.9% in the past year against the industry’s decline of 20%.
Image Source: Zacks Investment Research
More on FDA Approval of BMY’s Opdivo and Yervoy
The latest FDA approval was based on the results of the phase III CheckMate-8HW study.
This randomized, multicenter, open-label study is evaluating Opdivo plus Yervoy compared to Opdivo alone or chemotherapy in patients with unresectable MSI-H/dMMR mCRC.
Opdivo plus Yervoy met the dual primary endpoints of progression-free survival when compared to Opdivo monotherapy across all lines of therapy and chemotherapy in the first-line setting, as assessed by Blinded Independent Central Review.
The combination demonstrated a reduction in the risk of disease progression or death by 79% as compared to chemotherapy in the first-line setting and by 38% versus Opdivo monotherapy across all lines of therapy.
The approval was granted more than two months ahead of the target action date of June 23, 2025.
The study is ongoing to assess various secondary endpoints, including overall survival.
CRC, a type of cancer that develops in the colon or rectum, is the third most diagnosed cancer in the United States and an aggressive one that is difficult to treat.
Bristol Myers Squibb Company Price, Consensus and EPS Surprise
Blockbuster immuno-oncology drug Opdivo continues to maintain momentum on consistent label expansions.
The FDA approval of Opdivo Qvantig injection for subcutaneous use is expected to help extend the impact of its immuno-oncology franchise to patients into the next decade.
The European Commission approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
The Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) also recently recommended approval of Opdivo in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Opdivo as monotherapy as adjuvant treatment after surgical resection for the treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumors have PD-L1 expression ≥1%.
The CHMP also recommended approval of the subcutaneous formulation of Opdivo across multiple solid tumor indications.
BMY’s Growth Portfolio, comprising drugs like Reblozyl, Breyanzi, Camzyos and Opdualag, has stabilized its revenue base amid generic competition for its legacy drugs.
The company had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval of Cobenfy for schizophrenia broadens
BMY’s portfolio and validates the acquisition of Karuna Therapeutics.
BMY also recently agreed to acquire 2seventy bio, Inc. for $286 million. BMY and 2seventy bio have an agreement in place, whereby both companies equally share profits and losses related to the development, manufacturing and commercialization of Abecma in the United States.
In the past 60 days, estimates for Amicus’ earnings per share (EPS) have increased from 43 cents to 52 cents for 2025. During the same time frame, EPS estimates for 2026 have increased from 71 cents to 80 cents.
FOLD’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 45.42%.
ANI Pharmaceuticals
In the past 60 days, estimates for ANI Pharmaceuticals’ EPS have increased from $5.54 to $6.35 for 2025. During the same period, EPS estimates for 2026 have increased from $6.75 to $7.21. Year to date, shares of ANIP have rallied 14%. ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.32%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Shutterstock
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
Bristol Myers Squibb (BMY - Free Report) announced that it has obtained FDA approval for the label expansion of Opdivo (nivolumab) plus Yervoy (ipilimumab).
The regulatory body approved Opdivo plus Yervoy as a first-line treatment of adult and pediatric patients (12 years and older) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).
Please note that Opdivo , as a single agent or in combination with Yervoy, was previously granted accelerated approval in MSI-H/dMMR CRC in adult and pediatric patients (12 years and older) who have progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.
The latest FDA approval converts this second-line indication to full approval for Opdivo monotherapy and expands the indication for Opdivo plus Yervoy into the first-line setting.
Shares of BMY have risen 7.9% in the past year against the industry’s decline of 20%.
Image Source: Zacks Investment Research
More on FDA Approval of BMY’s Opdivo and Yervoy
The latest FDA approval was based on the results of the phase III CheckMate-8HW study.
This randomized, multicenter, open-label study is evaluating Opdivo plus Yervoy compared to Opdivo alone or chemotherapy in patients with unresectable MSI-H/dMMR mCRC.
Opdivo plus Yervoy met the dual primary endpoints of progression-free survival when compared to Opdivo monotherapy across all lines of therapy and chemotherapy in the first-line setting, as assessed by Blinded Independent Central Review.
The combination demonstrated a reduction in the risk of disease progression or death by 79% as compared to chemotherapy in the first-line setting and by 38% versus Opdivo monotherapy across all lines of therapy.
The approval was granted more than two months ahead of the target action date of June 23, 2025.
The study is ongoing to assess various secondary endpoints, including overall survival.
CRC, a type of cancer that develops in the colon or rectum, is the third most diagnosed cancer in the United States and an aggressive one that is difficult to treat.
Bristol Myers Squibb Company Price, Consensus and EPS Surprise
Bristol Myers Squibb Company price-consensus-eps-surprise-chart | Bristol Myers Squibb Company Quote
BMY Looks to Solidify Portfolio
Blockbuster immuno-oncology drug Opdivo continues to maintain momentum on consistent label expansions.
The FDA approval of Opdivo Qvantig injection for subcutaneous use is expected to help extend the impact of its immuno-oncology franchise to patients into the next decade.
The European Commission approved Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.
The Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) also recently recommended approval of Opdivo in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by Opdivo as monotherapy as adjuvant treatment after surgical resection for the treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumors have PD-L1 expression ≥1%.
The CHMP also recommended approval of the subcutaneous formulation of Opdivo across multiple solid tumor indications.
BMY’s Growth Portfolio, comprising drugs like Reblozyl, Breyanzi, Camzyos and Opdualag, has stabilized its revenue base amid generic competition for its legacy drugs.
The company had earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval of Cobenfy for schizophrenia broadens
BMY’s portfolio and validates the acquisition of Karuna Therapeutics.
BMY also recently agreed to acquire 2seventy bio, Inc. for $286 million. BMY and 2seventy bio have an agreement in place, whereby both companies equally share profits and losses related to the development, manufacturing and commercialization of Abecma in the United States.
BMY's Zacks Rank & Stocks to Consider
Bristol Myers currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Amicus Therapeutics, Inc. (FOLD - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , both carrying a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Amicus Therapeutics
In the past 60 days, estimates for Amicus’ earnings per share (EPS) have increased from 43 cents to 52 cents for 2025. During the same time frame, EPS estimates for 2026 have increased from 71 cents to 80 cents.
FOLD’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 45.42%.
ANI Pharmaceuticals
In the past 60 days, estimates for ANI Pharmaceuticals’ EPS have increased from $5.54 to $6.35 for 2025. During the same period, EPS estimates for 2026 have increased from $6.75 to $7.21. Year to date, shares of ANIP have rallied 14%.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.32%.